Remove Events Remove Labelling Remove Packaging
article thumbnail

GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion

Pharmaceutical Technology

The updated label for GE HealthCare’s positron emission tomography (PET) imaging agent Vizamyl (flutemetamol F 18 injection) now includes quantification of amyloid in the brain, meaning patients taking an anti-amyloid therapy can be monitored for the drug’s effectiveness. Don’t let policy changes catch you off guard.

article thumbnail

The IMA Group at ACHEMA 2024 : All-In-One solutions for the pharmaceutical sector

European Pharmaceutical Review

Solutions include washers, depyrogenating tunnels, liquid and powder filling and closing machines for vials, ampoules and Ready-To-Use (RTU), freeze dryers and relevant automatic loaders/unloaders, isolation technologies, labellers for vials and cartons and ancillary equipment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EU antibiotic shortages being monitored by MSSG

European Pharmaceutical Review

This has been exacerbated by geopolitical events such as war, the energy crisis and high inflation rates. A recent surge in respiratory infections has led to an increase in demand for antibiotics such as amoxicillin (alone and in combination with clavulanic acid), especially as paediatric formulations.

article thumbnail

ACI’s Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products – West Coast Edition

The FDA Law Blog

Claud will be speaking at the conference in a session titled “Crafting Your Safety Blueprint for Adverse Events and Recalls under MoCRA.” s John W.M. s John W.M. You can register for the conference here. FDA Law Blog readers receive a 10% discount off the tuition fee (promo code D10-999-FDA25 ).

article thumbnail

Insights+ Key Biosimilars Events of March 2023

PharmaShots

Udenyca is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation The approval was based on the comprehensive analytical data package, along with a PK, PD, and immunogenicity study. The results showed that 1171 out of 1605 patients were originator-naïve, retention rates @1yr.

FDA 49
article thumbnail

How AI and machine learning are transforming drug discovery

Pharmaceutical Technology

Through advanced AI-driven data curation, the platform extracts real-world insights from clinician notes, including reasons for GLP-1 therapy discontinuation such as adverse events and perceived lack of efficacy. It also identifies off-label usage patterns and relevant comorbidities that may influence therapeutic decisions.

article thumbnail

Insights+ Key Biosimilars Events of February 2023

PharmaShots

osteoporosis in postmenopausal women and men with high fractures risk, treatment-induced bone loss The submission was based on the comprehensive analytical and clinical data package, incl. It will be available as a 300mg concentrate for solution for infusion’ Related Post: Insights+ Key Biosimilars Events of January 2023

FDA 40